Cordance Medical has closed an oversubscribed $8 million seed financing round that exceeded its target, supporting the advancement of its noninvasive focused ultrasound platform designed to temporarily and safely open the blood-brain barrier. Sonder Capital led the round with participation from Shanda Grab Ventures, Angel Physician’s Fund, SmartGateVC, and R42. Additional investment came from The Sontag Foundation Innovation Fund and the Brain Tumor Investment Fund, a venture subsidiary of the National Brain Tumor Society, reflecting growing momentum around technologies that may improve the effectiveness of neuro-oncology treatments.
The company will use the capital to fund its first-in-human clinical trial evaluating its blood-brain barrier-opening technology. The platform is designed to increase the delivery efficiency of therapeutic agents into the brain, potentially expanding options for patients with brain cancer and other neurological conditions.
Cordance Medical differentiates its system with real-time monitoring of blood-brain barrier opening and patient-specific signal processing without requiring head fixation or live imaging during treatment. The company has secured FDA Breakthrough Device Designation in neuro-oncology and has recently received a grant from the National Cancer Institute to support its U.S. clinical trial. Built for scalable outpatient adoption, the system aims to create a practical pathway for both adult and pediatric patients to access blood-brain barrier-mediated therapies.
KEY QUOTES
“Our team is thrilled to announce this financing round and is grateful to all our investors for their confidence in our mission. Alongside our academic collaborators and industry partners, this strong syndicate backing reflects the urgent need for precision therapies in neurology, where patients face extremely limited treatment options. Combined with NIH support for our first in human trial, this funding accelerates our path to delivering transformative care.”
Bhaskar Ramamurthy, PhD, Co-founder and CEO of Cordance Medical
“Focused ultrasound continues to revolutionize treatment across multiple therapeutic areas. We believe that Cordance has the potential to establish new standards of care in neurology with a platform purpose built for practical, outpatient delivery of BBB mediated therapies for both pediatric and adult patients.”
Deborah Kilpatrick, PhD, Partner at Sonder Capital
